‘Slap in the Face’: Major Pro-Life Group Unloads on Trump Admin After DOJ Moves to Dismiss Abortion Pill Suits

The rift between the institutional pro-life movement and the Trump administration is growing wider as the administration continues to resist red-state efforts to restrict the availability of abortion pills.

Florida and Texas sued the Food and Drug Administration last year over the agency’s approval of the abortion drug Mifepristone. On Monday, the Department of Justice asked a judge to either dismiss the suit or delay a decision until the FDA has time to complete a new safety review of the drug, which was originally approved in 2000 and was made available by mail by the Biden administration during the Covid era.

“It’s a disgrace that pro-life states like Florida and Texas are having to fight the Trump-Vance administration in court to uphold their laws and that extremists like Gavin Newsom are being allowed to dictate their policy,” Marjorie Dannenfelser, SBA Pro-Life America president, said in a statement. “The Trump-Vance DOJ has clearly established a policy of siding with the abortion industry as it breaks laws, kills babies and harms women and girls.”

National Review has contacted the Department of Justice for comment on Dannenfelser’s claims.

The FDA approved a generic version of mifepristone and misoprostol in October, without reversing the Biden administration’s abortion drug mail-order policy, which allowed women to order the drugs online without an in-person medical visit.

The suit brought by Texas and Florida is one of several brought by red states challenging the safety and efficacy of Mifepristone and its availability by mail.

Just last week, the Department of Justice moved to dismiss Missouri v. FDA, claiming pro-life states and the women who claim to have experienced harm from the drugs lack standing.

Overall, 80 percent of Republican voters feel that the FDA should require in-person appointments before physicians can dispense abortion drugs, and 71 percent outright oppose the continuation of former President Joe Biden’s Covid-era mail-order abortion drug policy, according to a nationwide survey by Cyngal.

“Florida and Texas are the two biggest pro-life states in the country, with laws that protect more than 100,000 lives a year combined. But these laws cannot protect vulnerable people and the public health as long as the federal government is undermining them by leaving Biden’s mail-order abortion drug rule in place,” Dannenfelser said.

“This motion to dismiss is a slap in the face to red state allies everywhere, the MAHA movement, and Republicans’ deeply loyal pro-life base,” Dannenfelser said. “Our field team is on the ground in key battleground states, talking to voters at their doorsteps every day. Just eight months from midterms, the peril for the GOP is serious and growing.”

In December, SBA Pro-Life America demanded that Marty Makary, the U.S. Food and Drug Administration commissioner, be fired from his position, citing concerns that he “slow-walked” the agency’s abortion pill safety review.

Makary and Health and Human Services Secretary Robert F. Kennedy Jr. promised lawmakers and state attorneys general that the FDA was in the process of compiling a safety study on the chemical abortion drugs mifepristone and misoprostol. Yet Makary told officials to stall the review, Bloomberg reported.

Earlier this year, President Donald Trump encouraged GOP lawmakers to consider flexibility on the Hyde Amendment, a longstanding federal policy that prohibits federal funds like Medicaid from being used to fund abortions. The president floated this idea in an attempt to secure the success of his health care agenda through Congress.

Voters, however, also overwhelmingly support the Hyde Amendment.

According to the same Cyngal survey, 79 percent of Republican voters support maintaining the Hyde Amendment, and 30 percent say that if GOP leaders lessen their support of Hyde, they would be less enthusiastic about voting in the upcoming 2026 midterm elections.